Outpatient Addiction Treatment · Updated October 2026
MGM-15 & Oxonol Addiction Treatment in Tennessee
Outpatient MAT specialty clinic for MGM-15 dependence — the semi-synthetic 7-OH opioid analog sold in "research" supplements such as Oxonol. Same-week first appointments across Tennessee and North Georgia.
Yes. We treat MGM-15 dependence with buprenorphine, the same medication we use for 7-OH. Using it for 7-OH or MGM-15 is off-label. MGM-15’s legal status does not affect whether we can treat you.
MGM-15 (chemical name dihydro-7-hydroxymitragynine) is a semi-synthetic opioid. It does not occur in the kratom plant.
7-OH7-hydroxymitragynine, the concentrated kratom alkaloid
One chemical stepchemists convert 7-OH in a lab
MGM-15a compound that binds the brain’s mu-opioid receptors more strongly than 7-OH itself
2014First described in medicinal-chemistry research
Early 2025Began appearing in U.S. retail products
Oxonol (Real Botanicals)
A patient recently brought this product into our Chattanooga clinic.
MGM-15 is sold online and in smoke shops, vape shops, and gas stations, under brand names like Oxonol and as plain “MGM-15 tablets.” In Tennessee, the TBI told WSMV in September 2026 that it is seeing MGM-15 in some products sold as cat’s claw.
Must be 21+ to purchase
Supplement Facts
Serving Size: 1/2 Tablet
Servings Per Package: 100
Amount Per Serving
Proprietary Blend(MGM-15, Mitragynine)7.5 mg*
*Daily Value not established.
0 mg 7-Hydroxymitragynine per package 50 mg Mitragynine per package
Recreated from a product brought into our Chattanooga clinic — not the manufacturer's image.
Read the label twice
The panel advertises 0 mg 7-OH, which can read as the safer or more legal choice. But the listed active, MGM-15, is a laboratory-made cousin of 7-OH that works on the same opioid receptors. Removing 7-OH, the molecule regulators were moving against, and substituting an analog they had not yet scheduled is how products like this stayed on the shelf. The “proprietary blend” line also means the exact amount of MGM-15 per tablet is not disclosed.
Is MGM-15 safe?
There are no human safety studies on MGM-15. What is known comes from its chemistry and from how people present clinically: it acts on the same mu-opioid receptors as heroin, fentanyl, oxycodone, and 7-OH, and laboratory research describes it as a stronger opioid-receptor agonist than 7-OH.
Why poison-control centers and addiction clinicians treat these analogs as opioids rather than supplements:
Opioid-strength effects
No dosing studies
A “proprietary blend” that hides how much is in each tablet
Practical concerns we discuss with patients and families:
Sold as a supplement, opioid in effect.
The FDA considers 7-OH and its analogs sold as supplements or food to be unlawful, adulterated products under federal law. That position does not depend on scheduling, and federal agents seized roughly 73,000 units of 7-OH products from distributors in December 2025.
Flavored and chewable.
Strawberry candy-style tablets are easy to mistake for a benign supplement and easy to over-use.
Unknown dose per tablet.
A “proprietary blend” is not required to disclose how much MGM-15 it contains, so two products, or two batches, can be very different.
A rising poison-control signal.
The CDC reported that kratom-related poison-control calls climbed sharply over the past decade, a surge it attributed in part to high-potency semi-synthetic products in the 7-OH family. The data is reported at the category level, not for MGM-15 specifically.
Dependence and withdrawal
Because MGM-15 is an opioid, regular use produces tolerance and physical dependence, and stopping brings opioid-type withdrawal. There are no published studies measuring MGM-15 withdrawal specifically, so we will not put a day-by-day timeline on it the way we can for kratom and 7-OH. What we can say is grounded in mechanism: because MGM-15 binds the same mu-opioid receptors, withdrawal is expected to follow an opioid course — anxiety, muscle aches, GI symptoms, severe insomnia, and cravings — and the same buprenorphine-based treatment applies.
The treatment is the same medication-assisted treatment we use for kratom and 7-OH dependence. Buprenorphine products (Suboxone film and tablet, Sublocade injections, Brixadi injections) are FDA-approved for opioid use disorder. Restoration Recovery clinically uses buprenorphine off-label for MGM-15 dependence because MGM-15 is an opioid that binds the same receptors — which is why the medication compresses MGM-15 withdrawal the same way it compresses other opioid withdrawals (per SAMHSA TIP 63). Because there are no MGM-15-specific dosing studies, the doctor individualizes the plan at your first visit based on your reported use and your COWS score.
Your first visit takes 2 to 3 hours and follows our four-step intake: a DSM-5 substance use disorder assessment plus a COWS (Clinical Opiate Withdrawal Scale) score, then counseling intake, then doctor evaluation, then your prescription, with Sublocade or Brixadi ordered for you if you choose an injection. Be honest about what you have been using and when your last dose was — clinical decisions depend on accurate information, and anything you share is protected by HIPAA and 42 CFR Part 2, the federal rule that specifically shields addiction-treatment records.
Found one of these products in someone's things?
You do not need a diagnosis or certainty about what it is to call. Our intake team can tell you what the product is and walk through the options — for you or for someone you are worried about.
Restoration Recovery operates four outpatient MAT clinics. Each treats MGM-15, kratom, and 7-OH dependence with the same buprenorphine-based protocol. Walk-in appointments are not accepted; all visits are scheduled, and same-week intake is the standard at all four clinics.
Hours are 9:00 am to 4:30 pm Eastern Time on the days listed below:
All four clinics offer Suboxone film and tablet, oral medications for alcohol use disorder, individual counseling, telehealth follow-ups, and Hepatitis C care. If you choose Sublocade or Brixadi, the injections are given at our Chattanooga, Cleveland, or Ringgold clinic. Intensive Outpatient Programming (IOP) and integrated behavioral health are based at the Chattanooga clinic.
TennCare patient cost is typically $0 (BlueCare, Wellpoint, and UHC Community Plan) via the BESMART preferred-buprenorphine program at our TennCare-enrolled clinics. We are in-network with most major commercial carriers, including BCBS, UHC, Aetna, Cigna, and Humana — verify your specific plan. Self-pay is $250 per month flat, with medication billed separately.
Worried about someone using this?
MGM-15 acts on opioid receptors, so whatever its legal status where you are, we treat dependence on it with the same buprenorphine-based medication we use for other opioids. Call to talk through what someone is taking and what starting care looks like.
As of October 2026, MGM-15 is scheduled under federal law: a DEA temporary scheduling order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I effective August 26, 2026, through August 26, 2028 unless the order is extended, made permanent or replaced (91 FR 54948). On October 14, 2026 the DEA said it intends to split that order: MGM-15 and MGM-16 would get their own order with no change to their Schedule I status (91 FR 65381), and mitragynine pseudoindoxyl would move into a new order with 7-OH that covers amounts above a threshold. The August order stays in effect until the new orders are published. 7-OH itself is still not federally scheduled. The FDA recommended Schedule I for concentrated 7-OH in July 2025. The DEA published a notice of intent to temporarily schedule 7-OH above a specified threshold on July 6, 2026, and replaced that notice with a new one on October 14, 2026. No order has been issued yet. The FDA treats 7-OH and its analogs sold as supplements or food as unlawful, adulterated products, whether or not they are scheduled. That is its position under the Food, Drug, and Cosmetic Act, and the basis it used for the December 2025 seizures.
Several states have also acted on MGM-15, some before the federal order and some after it. Ohio scheduled dihydro-7-OH (MGM-15) by name as a Schedule I controlled substance, effective May 19, 2026. Florida placed MGM-15 in Schedule I in emergency rule 2ER26-2, effective August 18, 2026. In Missouri, the Attorney General reached a settlement in June 2026 barring a distributor from selling "dihydro-7-hydroxymitragynine ('MGM-15')". The state health department then added MGM-15 to Missouri’s controlled substance list in an emergency rule effective September 25, 2026, and has proposed a permanent version. On the same day, New Jersey announced that the federal order is now state law there, so MGM-15 is a controlled dangerous substance in New Jersey too.
In Tennessee, Matthew Davenport's Law (HB1649) took effect July 1, 2026 and bans the manufacture, delivery, sale, and knowing possession of kratom and 7-OH products. The statute covers "7-hydroxymitragynine and its derivatives," and MGM-15 is a derivative of 7-OH, so the ban is written to reach analogs like it. We are not aware of a Tennessee ruling that names MGM-15 specifically yet. Either way, the law does not restrict treatment: buprenorphine prescribing and clinic access continue unaffected. For the full picture, see our 7-OH scheduling tracker and the Tennessee ban law tracker.
Frequently asked questions
Is MGM-15 the same thing as kratom?
No. MGM-15 does not occur in the kratom plant. It is a laboratory-made opioid built from 7-OH, the concentrated kratom alkaloid. It binds the same mu-opioid receptors as heroin, fentanyl, and oxycodone, and laboratory research describes it as a stronger opioid-receptor agonist than 7-OH. It is sold as a "research" compound or dietary supplement, but clinically it behaves like an opioid.
I found a product like Oxonol or an "MGM-15" supplement. What is it?
It is a semi-synthetic opioid sold as a supplement. Oxonol (Real Botanicals) is a strawberry-flavored chewable whose label lists a "Proprietary Blend (MGM-15, Mitragynine)." Some of these products advertise "0 mg 7-OH," which can read as safer or more legal — but MGM-15 is itself a 7-OH analog in the same opioid class. If someone you know is using one, it is reasonable to treat it as opioid use and talk to a clinic. Our team can tell you what the product is and what the options are. Read our guide for families.
Can Suboxone or buprenorphine treat MGM-15 dependence?
Yes. Because MGM-15 acts on the same mu-opioid receptors as other opioids, the same buprenorphine-based medication-assisted treatment we use for kratom and 7-OH dependence is the mechanistically appropriate approach. Buprenorphine products (Suboxone film and tablet, Sublocade and Brixadi injections) are FDA-approved for opioid use disorder, and we use them off-label for MGM-15 dependence. There are no MGM-15-specific dosing or withdrawal studies, so the doctor individualizes care at the first visit.
Is MGM-15 legal in Tennessee?
No. Since August 26, 2026, a temporary DEA order has placed MGM-15 in Schedule I nationwide, including Tennessee (91 FR 54948). As of October 2026, MGM-15 is not separately named in Tennessee law. Tennessee's kratom and 7-OH ban took effect July 1, 2026 and covers "7-hydroxymitragynine and its derivatives." MGM-15 is a derivative of 7-OH, so the ban is written to reach analogs like it. Ohio, Florida and Missouri have scheduled it by name. Regardless of legal status, dependence on MGM-15 is treated the same way as any other opioid dependence.
How fast can I start treatment?
Same-week intake is the standard at all four of our clinics. First appointments can be as soon as the same day; you leave your first appointment with a Suboxone prescription, and your provider explains when to take your first dose at home; full stabilization takes 1-2 weeks. Follow-ups during stabilization are typically telehealth.
Talk to us
Restoration Recovery's intake team answers calls Monday through Friday, 9am to 4:30pm Eastern. After hours, leave a message or fill out the callback form and we will respond on the next business day. If you need help right now, the 988 Suicide & Crisis Lifeline and the free, confidential SAMHSA National Helpline (1-800-662-4357) are available 24/7.
